Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for ibandronate sodium submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2026-02-03FDA Approved: FOSAMAX PLUS D — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for Fosamax Plus D (alendronate sodium and cholecalciferol) submitted by Organon LLC.
-
FDA approval · 2026-02-03FDA Approved: ATELVIA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Atelvia (risendronate sodium) submitted by Allergan, Inc., to update/expand the product labeling…
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries' supplemental application for ibandronate sodium, indicating an updated approval status for t…
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for ibandronate sodium filed by Apotex Corp., under ANDA 204222.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Ibandronate Sodium submitted by Mylan Institutional LLC.
-
EMA approval · 2026-01-30EMA Authorised: Osvyrti (denosumab) — Accord Healthcare S.L.U.
The EMA authorised Osvyrti, a denosumab product from Accord Healthcare S.L.U., for bone resorption disorders including osteoporosis and post…
-
EMA approval · 2026-01-28EMA Authorised: Forsteo (teriparatide) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Forsteo (teriparatide) for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-27EMA Authorised: Optruma (raloxifene hydrochloride) — Eli Lilly Nederland B.V.
The EMA authorised Optruma (raloxifene hydrochloride) from Eli Lilly Nederland B.V. for osteoporosis in postmenopausal women.
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females [Phase 1]
This clinical trial update describes a Phase 1 study exploring whether blackcurrants can modify the gut microbiota and lower osteoporosis ri…
-
EMA approval · 2026-01-20EMA Authorised: Ponlimsi (denosumab) — Teva GmbH
The EMA authorised Ponlimsi (denosumab) by Teva GmbH on 19 January 2026 for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-14EMA Authorised: Stoboclo (denosumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Stoboclo (denosumab) by Celltrion Healthcare Hungary Kft. for osteoporosis, including postmenopausal osteoporosis.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: AGE Burden and Response to Antiresorptive Therapy in Osteoporosis
Clinical trial update from Bursa City Hospital evaluating the relationship between AGE burden and response to antiresorptive therapy in oste…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Lactobacillus Acidophilus and Postmenopausal Women [NA]
A clinical trial evaluating Lactobacillus acidophilus supplementation in postmenopausal women with bone loss/osteoporosis has completed, and…
-
EMA approval · 2026-01-06EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.
EMA authorised Obodence (denosumab) by Samsung Bioepis NL B.V. for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-05EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.
EMA authorised Junod, a denosumab product from Gedeon Richter, for osteoporosis and postmenopausal osteoporosis.
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis [Phase 4]
This clinical trial update discusses a Phase 4 study evaluating strategies for zoledronic acid after discontinuation of denosumab in postmen…
-
FDA approval · 2025-12-19FDA Approved: BONCRESA — Original Application (Amneal Pharmaceuticals LLC)
The FDA approved BONCRESA (denosumab-mobz) from Amneal Pharmaceuticals LLC under an Original Application. It is indicated for conditions tre…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients [Phase 4]
Phase 4 clinical trial evaluating cycle therapy versus sequential therapy with romosozumab and denosumab in postmenopausal osteoporosis; rec…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Relationship Between Periodontal Disease and Postmenopausal Osteoporosis
A completed clinical trial investigating the relationship between periodontal disease and postmenopausal osteoporosis.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Mechanisms of Anabolic Osteoporosis Therapy [NA]
Clinical trial update for a study on mechanisms of anabolic therapy for osteoporosis, sponsored by Massachusetts General Hospital, focusing …
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Bone Health in Postmenopausal Women: The Effect of Exercise With or Without Medication for Osteoporosis [NA]
This is a clinical trial update for a study assessing bone health in postmenopausal women, comparing exercise with and without medication fo…
-
EMA approval · 2025-12-02EMA Authorised: Izamby (denosumab) — Mabxience Research SL
The EMA authorised Izamby (denosumab) for osteoporosis-related bone resorption disorders, including postmenopausal osteoporosis, with Mabxie…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Telerehabilitation Versus Traditional Balance Training in Women With Osteoporosis. [NA]
This clinical trial update outlines a study comparing telerehabilitation to traditional balance training in postmenopausal women with osteop…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship [NA]
This clinical trial investigates how mechanical loading and bone loss affect motor neuron activity and H-reflex relationships in postmenopau…